The FDA has approved Takeda’s Orzeyful (oveporexton), the first therapy designed to address the underlying cause of narcolepsy type 1 in adults. Takeda’s orexin receptor 2 agonist marks a first-in-class approach in the U.S., following China National Medical Products Administration clearance for Orzeyful on July 22. The decision follows regulatory review based on clinical evidence for efficacy and safety in the adult narcolepsy type 1 population. With the FDA approval, Takeda moves Orzeyful into a commercial and guideline positioning moment—especially for patients who have had limited cause-based treatment options. For the sleep and neuropharma sector, the approval adds a major modality expansion beyond symptom-targeting therapies and reinforces the growing clinical momentum for orexin-system drug candidates.